In order to improve knowledge of MMR status in high-grade gliomas and in consideration of its possible predictive role of immune checkpoint inhibitor efficacy, we performed a large multicenter study to investigate the frequency and the type of immunohistochemical loss of MMR protein expression, its association with clinical, histological, and molecular characteristics, and its correlation with survival in HGG patients. This evidence concerns the gene MRC1 and glioma.